Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510247 | 0.84 | POLB (0.43) | ADRB2ADRB1ADRB3ABCB1KMT2A | |
| SCHEMBL8512591 | 0.84 | MEN1 (0.42) | ADRB2ADRB1ADRB3ABCB1KMT2A | |
| SCHEMBL8514353 | 0.83 | GRM2 (0.45) | ADRB2ADRB1ADRB3KMT2AGRM2 | |
| SCHEMBL8513172 | 0.83 | GRM2 (0.42) | ADRB2ADRB1ADRB3KMT2AGRM2 | |
| SCHEMBL8510265 | 0.83 | GRM2 (0.44) | ABCB1CYP2D6GRM2 | |
| SCHEMBL8513274 | 0.83 | GRM2 (0.44) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL8512529 | 0.83 | SCN1A (0.44) | ADRB2ADRB1ADRB3ABCB1KMT2A | |
| SCHEMBL8510157 | 0.83 | GRM2 (0.43) | ADRB2ADRB1ADRB3KMT2AGRM2 | |
| SCHEMBL9604237 | 0.82 | JAK2 (0.41) | ADRB2ADRB1ADRB3ABCB1KMT2A | |
| SCHEMBL8512821 | 0.81 | KMT2A (0.48) | ADRB2ADRB1ADRB3ABCB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | claimed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | ADRB2 675/4885ADRB1 1132/4885ADRB3 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.